6OD Stock Overview
A pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ODI Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.23 |
| 52 Week High | SEK 0.65 |
| 52 Week Low | SEK 0.21 |
| Beta | 0.62 |
| 11 Month Change | 2.63% |
| 3 Month Change | -48.46% |
| 1 Year Change | -45.58% |
| 33 Year Change | -51.15% |
| 5 Year Change | n/a |
| Change since IPO | -50.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6OD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -1.3% |
| 1Y | -45.6% | -22.0% | 7.4% |
Return vs Industry: 6OD underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 6OD underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 6OD volatility | |
|---|---|
| 6OD Average Weekly Movement | 12.7% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6OD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6OD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1 | Derek Simmross | www.odipharma.com |
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products under the Kandol brand. The company was founded in 2018 and is based in Stockholm, Sweden.
ODI Pharma AB (publ) Fundamentals Summary
| 6OD fundamental statistics | |
|---|---|
| Market cap | €4.24m |
| Earnings (TTM) | €30.95k |
| Revenue (TTM) | €1.95m |
136.8x
P/E Ratio2.2x
P/S RatioIs 6OD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6OD income statement (TTM) | |
|---|---|
| Revenue | SEK 22.45m |
| Cost of Revenue | SEK 17.66m |
| Gross Profit | SEK 4.78m |
| Other Expenses | SEK 4.43m |
| Earnings | SEK 355.97k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.023 |
| Gross Margin | 21.31% |
| Net Profit Margin | 1.59% |
| Debt/Equity Ratio | 0% |
How did 6OD perform over the long term?
See historical performance and comparison